The Gastrointestinal Cancer Channel is supported with funding from Gilead Sciences (Silver) and Revolution Medicines (Silver).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASCO 2022 | Second-line treatment strategies for pancreatic cancer
Alfredo Carrato, MD, PhD, Hospital Ramón y Cajal, Madrid, Spain, gives an overview of treatment options for patients who progress on first-line treatments for pancreatic cancer including taxane-based chemotherapy and gemcitabine. Oxaliplatin and 5-fluorouracil as part of FOLFOX as well as liposomal irinotecan (nal-IRI) are typically administered when patients progress from the current first-line treatments. This interview took place at the American Society of Clinical Oncology (ASCO) 2022 Annual Meeting in Chicago, IL.
